#JCLSpotlight: SGLT2i use in diabetic CAD patients was associated with modest LDL-C reductions and lower mortality/MACE risk, supporting further evaluation of their lipid-modifying role in secondary prevention. 🔗 https://ow.ly/OcLV50Z6kBY

#JCLSpotlight: Baseline apoB may drive long-term MACE recurrence in very young ACS survivors, highlighting its potential utility for risk stratification beyond traditional lipid markers. 🔗 https://ow.ly/VI1T50Z5BiG

#JCLSpotlight: LPL DNA methylation in adipose tissue differed in patients with PC compared with others, highlighting that different factors might contribute to PC and its associated risks. 🔗 https://ow.ly/ERfB50Z4HM6

#JCLSpotlight: Two-year pemafibrate treatment significantly improved liver stiffness & hepatic parameters in patients with MASLD, independent of weight loss or fat reduction, suggesting direct antifibrotic mechanisms. 🔗 https://ow.ly/sjVb50Z3nxF

#JCLSpotlight: Elevated RC baseline levels, variability & cumulative exposure are independently associated with increased stroke risk in patients with AF, underscoring the need for lipid-lowering strategies targeting RC. 🔗 https://ow.ly/Ghvh50Z2LZ6

The May edition of the Journal of Clinical Lipidology is LIVE & we're starting strong. #JCLSpotlight: Initiating triple LLT at ACS hospitalization may markedly reduce CV events through earlier and more complete LDL-C target achievement. 🔗https://ow.ly/4hxW50Z0nEt

#JCLSpotlight: Evinacumab achieved up to 82% LDL-C reduction in 2 autosomal recessive hypercholesterolemia cases — both without functional LDL receptors — highlighting the importance of early, intensive therapy. 📄https://ow.ly/gJ9h50YYs8b

#JCLSpotlight: A rare case of Niemann–Pick disease type B with sea-blue histiocytosis presenting as decompensated cirrhosis — where histopathology provided key diagnostic evidence when enzyme and genetic tests were unavailable. 📄 https://ow.ly/Rtxl50YW1CH

The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline joins the growing international consensus: Lp(a) should be tested at least once in all adults. Drs. Michael J. Wilkinson and Marlys L. Koschinsky discuss the implications in the JCL 👉 https://ow.ly/5WKF50YVKjB

#JCLSpotlight: Repeat Lp(a) testing is generally unnecessary but could be considered in those near risk thresholds or those being evaluated for Lp(a)-lowering therapies. Read more: https://ow.ly/wZ8T50YV3Jk

HoFH is the most severe and difficult-to-treat form of FH. On #HoFHAwarenessDay, we invite you to read National Lipid Association's expert clinical consensus on FH in the JCL, including updated guidance on HoFH treatment and management. 🔗https://ow.ly/4ZMu50YTgCk

#JCLSpotlight: Higher serum AIM levels were associated with altered lipid metabolites and predicted incident dyslipidemia, with the strongest link to elevated LDL-C seen in women. Read more: https://ow.ly/UUXQ50YSqoC

#JCLSpotlight: PCSK9 inhibition reduces LpPLA₂ and IP-10 without altering the global inflammatory response or HDL antioxidant function, suggesting a decrease in chronic vascular inflammation without broad systemic immune effects. 📄 https://ow.ly/HuOe50YRPsB

#JCLSpotlight: PAD carries high cardiovascular risk, yet many patients still don't receive guideline-recommended lipid-lowering therapy. A new narrative review explores the unmet needs and health inequities driving this gap. 📄https://ow.ly/P6kP50YR655

#JCLSpotlight: In a real-world observational study, inclisiran demonstrated significant LDL-C reductions within 1 year. Plus, insights on patient out-of-pocket costs. 👉 Read more: https://ow.ly/QtnW50YQxgK#JCLSpotlight

#JCLSpotlight: Pemafibrate effectively & safely reduced LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels, offering a potential new therapeutic option. Read more: https://ow.ly/oCrP50YPb1P

#JCLSpotlight: A text-based Health platform showed high interactivity & acceptability for tracking statin-associated muscle symptoms over time. Read more from the study: https://ow.ly/ECuU50YEFyV

#JCLSpotlight: Elevated Lp(a) was found in 8.3% of the general population & up to 23.9% in those with ASCVD. Adding Lp(a) as a risk enhancer improved risk reclassification beyond HellenicSCOREII+ in two Greek cohorts. Read more: https://ow.ly/jXMT50YCr6E

#JCLSpotlight: Poor sleep quality is linked to unfavorable lipid profiles, especially elevated sdLDL-C levels. Treating sleep quality as a modifiable lifestyle factor may help reduce lipid abnormalities and prevent CVD. Read more: https://ow.ly/vayN50YBKQB#JCLSpotlight

#JCLSpotlight | #NationalTriglyceridesDay Rare late-onset FCS case highlights: ▪️ Delayed diagnosis → pancreatic insufficiency and malnutrition ▪️ Statin and pioglitazone withdrawal → improved clinical status ▪️ Volanesorsen → 74% triglyceride reduction from baseline Read: https://ow.ly/7W9g50YzLPX

#JCLSpotlight from the March Issue: Obese patients with diabetes and CAD who achieved LDL-C <1.8 mmol/L showed greater coronary atheroma regression than nonobese patients. Read more: https://ow.ly/7V3F50YzlU1#JCLSpotlight

Spotlighting #LpaAwarenessDay with two recent JCL studies on Lp(a) testing: 1️⃣ Barriers & facilitators to Lp(a) testing: https://ow.ly/Gsmc50Yyich 2️⃣ QI study increases Lp(a) testing in outpatient cardiology clinic: https://ow.ly/exM350Yyicg#LpaAwarenessDay #KnowLpa

#JCLSpotlight: Two pediatric cases of early death from FH, alongside a systematic review of childhood and adolescent FH-related deaths, reveal diagnostic delays and inadequate treatment as common contributing factors. Read more about the findings: https://ow.ly/oG7L50YxyGv

#JCLSpotlight: A rare variant in SCARB1 — p.(Thr378Met) — impairs SR-B1-mediated HDL uptake and is associated with elevated HDL-C levels, supporting SCARB1 as a candidate gene for genetic screening in patients with dyslipidemia. Read more: https://ow.ly/yPhX50YwXV1

#JCLSpotlight: The BALANCE study shows olezarsen 80 mg reduced all-cause inpatient service utilization and improved the experience of patients with FCS after just one year of treatment. Read more: https://ow.ly/AICF50Yw3ea

The Journal of Clinical Lipidology is growing!📈 Our 2025 CiteScore climbed to 6.8, a reflection of the high-quality research and dedicated community behind every issue. #Lipidology #ClinicalResearch

The JCL February issue is live!📰 First in the #JCLSpotlight: A meta-analysis of 92 studies found carotid plaque in 23% of asymptomatic adults (18–65), rising from 5.2% (18–45) to 30.3% (50–65) and higher in men vs women. Read more: https://ow.ly/qpxv50YqaC2

The NLA’s newest meta-analysis shows that in CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated w/ a 30% RRR in 4-point MACE. These findings support LDL-C lowering early in the life course: https://ow.ly/32o050YpGI4

On #WorldObesityDay, we invite you to explore the #JCLSpecialEdition on obesity, which brings together multidisciplinary insights for clinicians, researchers, educators, and public health leaders. Read the issue: lipidjournal.com/issue/S1933-2874(26)X0002-2#WorldObesityDay

#JCLSpecialEdition #Obesity Diagnosis and management of CVD risk factors is an important aspect of an obesity management plan. Evidence shows treatment with liraglutide, semaglutide, and/or bariatric surgery lowers CVD events and mortality. Explore the full findings: https://ow.ly/LtnK50Yofyb

#JCLSpecialEdition #Obesity A key characteristic of obesity is adipocytopathic atherogenic dyslipidemia. This review highlights the lipid specialist’s role in team-based obesity care to address cardiometabolic risk and improve long-term outcomes. Read now: https://ow.ly/GOtQ50YmuEM

#JCLSpecialEdition #Obesity Childhood obesity is a distinct condition with unique management needs. This review covers rising prevalence, genetic/environmental drivers, comorbidities & current treatments (IHBLT, metabolic surgery & pharmacotherapy). Read now: https://ow.ly/AMmG50YlV5S

#JCLSpecialEdition #Obesity Obesity management requires destigmatization and recognition as a chronic disease. This article highlights the role of GLP-1 RAs in achieving >10% weight loss with CV-kidney-metabolic benefits. Read more: https://ow.ly/4QkW50Yl0Kv

NOW LIVE: #JCLSpecialEdition: Obesity as a Cardiometabolic Disease How is obesity defined? This article evaluates the benefits and disadvantages of current and proposed measures to characterize obesity. Read the review: https://ow.ly/xEBf50YkcVj

#JCLSpotlight: A BPA alert for patients with LDL-C ≥ 190 mg/dL increased statin use (39.4%→61.7%), reduced LDL-C by 84.1 mg/dL, and raised FH diagnoses (2.3%→6.0%). Electronic messaging may improve treatment and detection. #HeartMonth Read more: https://ow.ly/cxPq50Yhatl

#JCLSpotlight: In a new analysis of the CLEAR Outcomes trial, adding lipid-modifying therapy after randomization did not impact the observed results of the trial. Read more: https://ow.ly/Xi4P50YeBq2#JCLSpotlight

#JCLSpotlight A pilot trial shows artichoke leaf extract reduced liver steatosis and size and improved body composition in patients with obesity and MASLD, while noting a significant transaminase increase. 🔗Read more: https://ow.ly/BXZA50Ye3e4

#JCLSpotlight: Elevated relative fat mass is strongly associated with a higher prevalence of sleep disorders in U.S. adults, highlighting adiposity as a modifiable factor in sleep health and prevention strategies. Read more: https://ow.ly/HpRT50YbKoh#JCLSpotlight

Last week, the NLA released its updated expert clinical consensus on familial hypercholesterolemia. The guidance covers refined diagnostic criteria, genetic testing, cascade screening, and updated management strategies, including therapies for HoFH and HeFH. #HeartMonth 🔗https://ow.ly/mm1w50Y90l7

#JCLSpotlight: Lomitapide effectively and safely reduced TG levels in FCS patients with prior pancreatitis over a nearly 3-year follow-up period. Results were consistent with open-label trial data despite a lower median dose, with no new safety signals observed. 🔗https://ow.ly/F0B650Y8X43

#JCLRoundtable: A European Perspective on Lipid Management & CV Health Global experts Drs. Kausik Ray, Børge Nordestgaard, and P. Barton Duell discuss early LDL-C lowering, combination therapy, Lp(a) screening, FH, and what’s next in CV prevention. Read the discussion: https://ow.ly/QJCH50Y544I#JCLRoundtable

#JCLSpotlight: New research shows men and women have distinct inflammatory responses during long-term evolocumab therapy, highlighting the importance of sex-specific considerations in CV risk management and treatment monitoring. Read more: https://ow.ly/Fa8B50Y3Utv

#JCLSpotlight: New research shows PCSK9 inhibitors and inclisiran significantly reduce visit-to-visit LDL-C variability vs standard therapy. Lower LDL-C variability was linked to fewer CV events, highlighting lipid stability as a key treatment goal. Read more: https://ow.ly/qLkI50Y0Gbh

The January JCL issue is live!📘 #JCLSpotlight: A pooled analysis of phase 3 ODYSSEY studies shows that in patients with ASCVD (without prior ACS or stroke), alirocumab significantly reduced LDL-C vs placebo or ezetimibe. Read more: https://ow.ly/QZrQ50Y0eyy

🚨Deadline Extended!🚨 You now have until January 12 at 11:59 PM ET to submit your abstract for the 2026 #NLASessions. Take advantage of this extension and make sure your research is part of the premier meeting in lipidology! 🔗Submit now: lipid.org/abstracts

#JCLSpotlight: High plasma Lp(a) is linked to increased IFN-γ–associated gene expression in classical monocytes and elevated CXCL10 in those without ASCVD, while chromatin accessibility remains unchanged across groups. Read more: https://ow.ly/NENz50XKWcC

#JCLSpotlight: New data from the Balance study shows strong concordance between NAFCS Score ≥45 and a positive genetic diagnosis of FCS. The score can clinically support an FCS diagnosis when genetic testing isn’t available or is indeterminate. Read more: https://ow.ly/7EBj50XKW2h

#JCLSpotlight: 2/3 of statin-intolerant patients report self-medication—often pain meds, vitamin D, electrolytes & omega-3s. None linked to lower LDL-C. Over half report negative statin messaging, highlighting the need for proactive guidance. Read more: https://ow.ly/gcoj50XKVUj#JCLSpotlight

#JCLSpotlight: Data from a phase 2b trial suggests evinacumab may help lower triglycerides in patients with sHTG and a history of sHTG-associated acute pancreatitis. Learn more: ow.ly/h3wn50XHFVh

#JCLSpotlight: Current lipid-lowering therapies have only modest impact on Lp(a), but new RNA-targeted agents are showing promise. Pelacarsen—an antisense oligonucleotide—reduced Lp(a) by ≥80% in phase 2b and is now in multiple phase 3 trials. Read more: ow.ly/T6Jy50XBZhz